NMI TT

We are proud to announce the availability of DigiWest® and RPPA multiplex protein profiling from FFPE samples

25.9.2018 | New Publication

Study published on hiPS cardiomyocytes for drug proarrhythmic potential assessment

International multisite study of human induced pluripotent stem cell-derived cardiomyocytes for drug proarrhythmic potential assessment

31.5.2018 | CRISPR/Cas9 License

CRISPR/Cas9 license for NMI TT Pharmaservices

ERS Genomics licenses CRISPR/Cas9 genome editing patents to NMI and NMI TT Pharmaservices

8.11.2017 | New Service

New service: DigiWest® pathway panels

We are pleased to announce the availability of pathway panels for our DigiWest® multiplex immunoassay-based protein profiling services

11.9.2017 | New Product

NMI TT takes over ZeptoCHIP supply

NMI TT takes over global Zeptosens chip supply for RPPA protein profiling studies

28.8.2017 | New Offering

Modified Luminex bead products

We are excited to announce our most recent offering: modified MagPlex® microspheres for Luminex® assays

22.6.2017 | Grant Awarded

Grant to NMI TT Pharmaservices and Charité for development of protein profiling

NMI TT Pharmaservices and Charité received a grant for protein profiling in individualization of tumor therapy

4.11.2016 | CiPA Core Site

NMI core site in CiPA myocyte study

We are very excited that HESI changed our status from non-core to core site for the actual running CiPA myocyte study

26.9.2016 | New Publication

DigiWest published in Nature Communications

NMI and its CRO NMI TT Pharmaservices announce the publication of their proprietary DigiWest® protein profiling method in Nature Communications

1.8.2016 | Workshop

6th Global RPPA workshop

Come to Reutlingen, and hear about the latest advances in Reverse Phase Protein Arrays (RPPAs) and their application for biomarker research

2.5.2016 | Grant Awarded

Eurostars grant for Sentinel Oncology and NMI TT Pharmaservices

Sentinel Oncology and NMI TT Pharmaservices awarded Eurostars grant for development of a novel biomarker for treatment of Fragile X Syndrome (FXS)

9.1.2016 | New Product

New Cav1.2 cell line

Cav1.2 ion channels are expressed in heart, smooth muscle and neurons, and therefore are therapeutic targets in cardiac arrhythmia and hypertension

22.9.2015 | New Branch

NMI TT Pharmaservices establishes new branch in Berlin

NMI TT Pharmaservices today announced that it is growing its operations by establishing a new branch at the Bayer CoLaborator in Berlin

News

PLoS Genetics paper on modeling of tumor heterogeneity

New service: DigiWest® and RPPA from FFPE samples